Paper21397858
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening.
Sawey ET and 13 others. Cancer Cell, 2011. Cited by 375 papers, by iCite.
Cite this record
ConductScience Library. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Papers, record 21397858. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21397858
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Fibroblast Growth Factors | Major topic |
| Liver Neoplasms | Major topic |
| Oncogene Proteins | Major topic |
| Animals | |
| Antibodies, Monoclonal | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Chromosomes, Human, Pair 11 | |
| Cyclin D1 | |
| Female | |
| Gene Amplification | |
| Gene Expression Regulation, Neoplastic | |
| Genetic Predisposition to Disease | |
| Genomics | |
| Humans | |
| Immunoblotting | |
| Mice | |
| Mice, Nude | |
| RNA Interference | |
| Tumor Burden | |
| Xenograft Model Antitumor Assays |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| CA076905 | NCI NIH HHS | United States | K12CA076905 | PubMed and NIH | NIH RePORTER |
| R01 CA124648 | NCI NIH HHS | United States | R01CA124648 | PubMed and NIH | NIH RePORTER |
| RC2 CA148532 | NCI NIH HHS | United States | RC2CA148532 | PubMed and NIH | NIH RePORTER |
| CA148532 | NCI NIH HHS | United States | RC2CA148532 | PubMed and NIH | NIH RePORTER |
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH | NIH RePORTER |
| U01 CA105388 | NCI NIH HHS | United States | U01CA105388 | PubMed and NIH | NIH RePORTER |
| P01 CA013106 | NCI NIH HHS | United States | P01CA013106 | PubMed and NIH | NIH RePORTER |
| CA105388 | NCI NIH HHS | United States | U01CA105388 | PubMed and NIH | NIH RePORTER |
| CA124648 | NCI NIH HHS | United States | R01CA124648 | PubMed and NIH | NIH RePORTER |
| K12 CA076905 | NCI NIH HHS | United States | K12CA076905 | PubMed and NIH | NIH RePORTER |
References48
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19366792 | Identification of potential driver genes in human liver carcinoma by genomewide screening. | Cancer Res | 2009 | https://conductscience.org/library/papers/19366792 | PubMed |
| 2 | 20018895 | FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. | J Biol Chem | 2010 | https://conductscience.org/library/papers/20018895 | PubMed |
| 3 | 18980784 | RNA polymerases I and III, non-coding RNAs and cancer. | Trends Genet | 2008 | https://conductscience.org/library/papers/18980784 | PubMed |
| 4 | 15946945 | Cyclin D1 is not an immediate target of beta-catenin following Apc loss in the intestine. | J Biol Chem | 2005 | https://conductscience.org/library/papers/15946945 | PubMed |
| 5 | 10984191 | Protective effect of supplemental superoxide dismutase on survival of neuronal cells during starvation. Requirement for cytosolic distribution. | J Mol Neurosci | 2000 | https://conductscience.org/library/papers/10984191 | PubMed |
| 6 | 11408803 | Disruption of the p16/cyclin D1/retinoblastoma protein pathway in the majority of human hepatocellular carcinomas. | Oncology | 2001 | https://conductscience.org/library/papers/11408803 | PubMed |
| 7 | 12975311 | Representational oligonucleotide microarray analysis: a high-resolution method to detect genome copy number variation. | Genome Res | 2003 | https://conductscience.org/library/papers/12975311 | PubMed |
| 8 | 17599042 | Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. | Oncogene | 2008 | https://conductscience.org/library/papers/17599042 | PubMed |
| 9 | 18593907 | Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. | Cancer Res | 2008 | https://conductscience.org/library/papers/18593907 | PubMed |
| 10 | 18347015 | Roles of Pofut1 and O-fucose in mammalian Notch signaling. | J Biol Chem | 2008 | https://conductscience.org/library/papers/18347015 | PubMed |
| 11 | 11454681 | Hepatocellular carcinoma results from chronic cyclin D1 overexpression in transgenic mice. | Cancer Res | 2001 | https://conductscience.org/library/papers/11454681 | PubMed |
| 12 | 17511024 | Genetics of hepatocellular carcinoma. | World J Gastroenterol | 2007 | https://conductscience.org/library/papers/17511024 | PubMed |
| 13 | 9552382 | A temporal and biochemical link between growth factor-activated MAP kinases, cyclin D1 induction and cell cycle entry. | Prog Cell Cycle Res | 1996 | https://conductscience.org/library/papers/9552382 | PubMed |
| 14 | 20160489 | Differences underlying EGFR and HER2 oncogene addiction. | Cell Cycle | 2010 | https://conductscience.org/library/papers/20160489 | PubMed |
| 15 | 12057932 | A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. | Am J Pathol | 2002 | https://conductscience.org/library/papers/12057932 | PubMed |
| 16 | 12676587 | Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. | Cancer Cell | 2003 | https://conductscience.org/library/papers/12676587 | PubMed |
| 17 | 18701503 | Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. | Cancer Res | 2008 | https://conductscience.org/library/papers/18701503 | PubMed |
| 18 | 10066073 | HER-2/neu as a predictive marker of response to breast cancer therapy. | Breast Cancer Res Treat | 1998 | https://conductscience.org/library/papers/10066073 | PubMed |
| 19 | 12923544 | Chromosome aberrations in solid tumors. | Nat Genet | 2003 | https://conductscience.org/library/papers/12923544 | PubMed |
| 20 | 18451130 | Oncogene addiction. | Cancer Res | 2008 | https://conductscience.org/library/papers/18451130 | PubMed |
Cited by229
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 375 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42640574 | Phase 2 study of futibatinib in combination with pembrolizumab in patients with FGF19 expressing advanced hepatocellular carcinoma. | Oncologist | 2026 | https://conductscience.org/library/papers/42640574 | PubMed |
| 42491058 | The role of FGF19-FGFR4 signaling pathway in liver health and disease: Guardian or destroyer. | Genes Dis | 2026 | https://conductscience.org/library/papers/42491058 | PubMed |
| 41737892 | Lactylation-related genes signature panel in hepatocellular carcinoma reveals the prognostic and therapeutic optimization. | Mol Cell Oncol | 2026 | https://conductscience.org/library/papers/41737892 | PubMed |
| 41716515 | Targeted therapy for liver cancer: Current status and future directions. | Bioimpacts | 2025 | https://conductscience.org/library/papers/41716515 | PubMed |
| 41328353 | FGF19 in Solid Tumors: Molecular Mechanisms, Metabolic Reprogramming, and Emerging Therapeutic Opportunities. | Theranostics | 2026 | https://conductscience.org/library/papers/41328353 | PubMed |
| 41301037 | Transforming Liver Cancer Therapy: Integrating Molecular Profiling with Precision and Transplant-Based Care. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/41301037 | PubMed |
| 41097083 | Reactivation of the PI3K/mTOR Signaling Pathway Confers Resistance to the FGFR4 Inhibitor FGF401. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/41097083 | PubMed |
| 41045933 | Updated efficacy and predictive biomarkers of QL1706, a bifunctional PD-1/CTLA-4 dual blocker in advanced solid tumors-A phase 1/1b study. | Cell Rep Med | 2025 | https://conductscience.org/library/papers/41045933 | PubMed |
| 40977663 | Fibroblast growth factor 19-fibroblast growth factor receptor 4 axis: From oncogenesis to targeted-immunotherapy in advanced hepatocellular carcinoma. | World J Gastrointest Oncol | 2025 | https://conductscience.org/library/papers/40977663 | PubMed |
| 40286076 | Protein O-Fucosyltransferases: Biological Functions and Molecular Mechanisms in Mammals. | Molecules | 2025 | https://conductscience.org/library/papers/40286076 | PubMed |
| 39976135 | Integrative Multi-Omics Approaches Reveal Selectivity Profiles and Molecular Mechanisms of FIIN-2, a Covalent FGFR Inhibitor. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/39976135 | PubMed |
| 39958385 | Microbial transformations of bile acids and their receptors in the regulation of metabolic dysfunction-associated steatotic liver disease. | Liver Res | 2023 | https://conductscience.org/library/papers/39958385 | PubMed |
| 39915447 | Hepatocellular carcinoma: signaling pathways and therapeutic advances. | Signal Transduct Target Ther | 2025 | https://conductscience.org/library/papers/39915447 | PubMed |
| 39875570 | FGF-based drug discovery: advances and challenges. | Nat Rev Drug Discov | 2025 | https://conductscience.org/library/papers/39875570 | PubMed |
| 39682130 | Resistance to Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma (HCC): Clinical Implications and Potential Strategies to Overcome the Resistance. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/39682130 | PubMed |
| 39567523 | A developmental biliary lineage program cooperates with Wnt activation to promote cell proliferation in hepatoblastoma. | Nat Commun | 2024 | https://conductscience.org/library/papers/39567523 | PubMed |
| 39522105 | Lenvatinib inhibits cholangiocarcinoma progression by targeting the FGF19/PI3K/AKT signaling pathway. | Apoptosis | 2025 | https://conductscience.org/library/papers/39522105 | PubMed |
| 39220834 | Team players in the pathogenesis of metabolic dysfunctions-associated steatotic liver disease: The basis of development of pharmacotherapy. | World J Gastrointest Pathophysiol | 2024 | https://conductscience.org/library/papers/39220834 | PubMed |
| 39006147 | Cross talk between genetics and biochemistry in the pathogenesis of hepatocellular carcinoma. | Hepatol Forum | 2024 | https://conductscience.org/library/papers/39006147 | PubMed |
| 38981913 | Fibroblast growth factor receptor 4 deficiency in macrophages aggravates experimental colitis by promoting M1-polarization. | Inflamm Res | 2024 | https://conductscience.org/library/papers/38981913 | PubMed |
Genes43
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21397858
GET https://conductscience.org/api/papers/v1/21397858/references?page=2